英夫利西单抗与乌司奴单抗在生物制剂初治克罗恩病中实现内镜及透壁缓解的疗效比较
这项前瞻性真实世界队列研究纳入429例生物制剂初治的克罗恩病患者(英夫利西单抗283例、乌司奴单抗146例),比较两种药物在第14至26周和第44至56周的内镜缓解、内镜应答、透壁缓解、透壁应答、临床缓解及C反应蛋白缓解。结果显示两组在各主要结局上均无显著差异,仅英夫利西单抗组第14至26周C反应蛋白缓解率较高,但第44至56周两组相似,倾向性评分匹配队列结果一致。
要点
- 生物制剂初治克罗恩病患者中,英夫利西单抗与乌司奴单抗在内镜缓解、透壁缓解等方面疗效相似。
- 第14至26周英夫利西单抗组C反应蛋白缓解率较高(aOR 1.85,95%CI 1.17-2.93),但第44至56周两组相似。
- 至第56周,两组治疗中断率相当(24.4% vs 20.5%,P=.372)。
核心结论
- 在生物制剂初治的克罗恩病患者中,英夫利西单抗与乌司奴单抗在实现临床、内镜及透壁缓解方面显示出相似的疗效。
研究设计与样本
- 前瞻性真实世界队列研究,纳入生物制剂初治并开始英夫利西单抗或乌司奴单抗治疗的克罗恩病患者,共429例(英夫利西单抗283例,乌司奴单抗146例)。
- 采用多元逻辑回归和倾向性评分匹配校正混杂因素,比较第14至26周和第44至56周的疗效结局。
主要发现
- 第14至26周,英夫利西单抗组与乌司奴单抗组的内镜缓解率分别为37.5% vs 30.8%(aOR 1.42,95%CI 0.89-2.25),无显著差异。
- 第44至56周,两组内镜缓解率分别为37.5% vs 35.6%(aOR 1.10,95%CI 0.71-1.72),无显著差异。
- 第14至26周,两组透壁缓解率分别为16.7% vs 14.7%(aOR 1.23,95%CI 0.64-2.38),第44至56周分别为30.0% vs 28.7%(aOR 1.10,95%CI 0.65-1.87),均无显著差异。
- 第14至26周,英夫利西单抗组C反应蛋白缓解率高于乌司奴单抗组(60.1% vs 61.6%;aOR 1.85,95%CI 1.17-2.93),但第44至56周两组相似(72.8% vs 71.4%;aOR 0.99,95%CI 0.65-1.52)。
- 至第56周,英夫利西单抗组与乌司奴单抗组的治疗中断率相当(24.4% vs 20.5%;P=.372)。
关键数值与推荐
- 第14至26周临床缓解率:英夫利西单抗组73.2% vs 乌司奴单抗组62.3%(aOR 1.54,95%CI 0.96-2.48)。
- 第44至56周临床缓解率:英夫利西单抗组73.5% vs 乌司奴单抗组71.2%(aOR 1.14,95%CI 0.71-1.85)。
- 第14至26周内镜应答率:英夫利西单抗组60.8% vs 乌司奴单抗组55.5%(aOR 1.27,95%CI 0.83-1.95)。
- 第44至56周内镜应答率:英夫利西单抗组52.7% vs 乌司奴单抗组49.3%(aOR 1.14,95%CI 0.75-1.76)。
- 第14至26周透壁应答率:英夫利西单抗组40.1% vs 乌司奴单抗组34.1%(aOR 1.23,95%CI 0.76-2.00);第44至56周分别为47.6% vs 42.6%(aOR 1.19,95%CI 0.75-1.90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Active-comparator studies are important to clinical decision-making. We compared the effectiveness of infliximab vs ustekinumab for endoscopic and transmural remission in biologic-naïve Crohn's disease (CD). METHODS: This was a prospective real-world cohort study that included biologic-naïve patients with CD initiating infliximab or ustekinumab therapy. We compared endoscopic remission, endoscopic response, transmural remission, transmural response, clinical remission, and C-reactive protein (CRP) remission at weeks 14 to 26 and 44 to 56, using multiple logistic regression and propensity score matching to adjust for confounders. RESULTS: In total, 429 patients were included (283 infliximab and 146 ustekinumab). At weeks 14 to 26 and 44 to 56, no significant differences were found between infliximab and ustekinumab groups in the rates of endoscopic remission (37.5% vs 30.8%; adjusted odds ratio [aOR], 1.42; 95% confidence interval [CI], 0.89-2.25; 37.5% vs 35.6%; aOR, 1.10; 95% CI, 0.71-1.72), endoscopic response (60.8% vs 55.5%; aOR, 1.27; 95% CI, 0.83-1.95; 52.7% vs 49.3%; aOR, 1.14; 95% CI, 0.75-1.76), transmural remission (16.7% vs 14.7%; aOR, 1.23; 95% CI, 0.64-2.38; 30.0% vs 28.7%; aOR, 1.10; 95% CI, 0.65-1.87), transmural response (40.1% vs 34.1%; aOR, 1.23; 95% CI, 0.76-2.00; 47.6% vs 42.6%; aOR, 1.19; 95% CI, 0.75-1.90), and clinical remission (73.2% vs 62.3%; aOR, 1.54; 95% CI, 0.96-2.48; 73.5% vs 71.2%; aOR, 1.14; 95% CI, 0.71-1.85). The infliximab group had a higher CRP remission rate at weeks 14 to 26 (60.1% vs 61.6%; aOR, 1.85; 95% CI, 1.17-2.93), but rates were similar at weeks 44 to 56 (72.8% vs 71.4%; aOR, 0.99; 95% CI, 0.65-1.52). By week 56, treatment discontinuation rates were also comparable between the infliximab and ustekinumab groups (24.4% vs 20.5%; P = .372). Similar results were replicated in the propensity-matched cohort. CONCLUSIONS: Infliximab and ustekinumab demonstrated similar effectiveness in achieving clinical, endoscopic, and transmural remission in biologic-naïve patients with CD.
引用
- Huang Z, Diao N, Guo Q, et al. Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn's Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40239731. doi:10.1016/j.cgh.2024.12.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。